Gui-Lin Yu

Immunotherapy in advanced biliary tract cancer: current status and future directions

Biliary tract cancers (BTCs) are aggressive, molecularly heterogeneous malignancies, and most patients present with unresectable or metastatic disease at diagnosis. For more than a decade, gemcitabine–platinum chemotherapy served as the first-line standard of care, with only modest survival benefit. The phase 3 TOPAZ-1...